Factive tablet receives marketing approval from Health Canada

Published: 2004-03-17 06:57:00

Updated: 2004-03-17 06:57:00

GenomeTherapeutics Corporation announced on March 12 that it has received marketing approval for Factive (gemifloxacin mesylate) for the treatment of acute bacterial exacerbations of chronic bronchitis from the Therapeutic Products Directorate of health Canada.

Factive tablet is an orally administered, broad-spectrum fluoroquinolone antibiotic to which GenomeTherapeutics has licensed all N...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.